| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the preceding three months, 4 analysts have released ratings for Entrada Therapeutics (NASDAQ:TRDA), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.75, a high estimate of $28.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 5.81% from the previous average price target of $21.50.
A comprehensive examination of how financial experts perceive Entrada Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Francois Brisebois | Oppenheimer | Raises | Outperform | $28.00 | $25.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $20.00 | $18.00 |
| Francois Brisebois | Oppenheimer | Maintains | Outperform | $25.00 | $25.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $18.00 | $18.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Entrada Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Entrada Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Entrada Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 421.16%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Entrada Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 58.11% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Entrada Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.74% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 10.07%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.15, Entrada Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TRDA
